Podcasts about crswnp

In this episode, host Dr. Amber Luong speaks with Drs. Alan Workman and Jim Palmer. They discuss the recently published Original Article: “The Completeness of Surgery Index Predicts Success in CRSwNP With Asthma by SNOT-22 and Asthma Control Test”. The full manuscript is available in the International Forum of Allergy and Rhinology. Listen and subscribe […]

Keeping up with the allergy literature can feel like a second job layered onto an already full clinic day. Between evolving guidelines, expanding biologic options, and long-held assumptions quietly being challenged, it's hard to know which papers are worth slowing down for. This episode takes a deliberately selective approach. Dr. David Khan — chair of the American College of Allergy, Asthma, and Immunology literature review — walks through five papers from 2025 that stood out not because they were flashy, but because they asked practical questions allergists actually wrestle with in clinic.Timing of repeat epinephrine to inform pediatric anaphylaxis observation periods: a retrospective cohort studyFor most children treated with epinephrine, prolonged emergency department observation may be unnecessary, with two hours appearing sufficient unless cardiovascular features are involved.Two-year data of tapered dupilumab shows high effectiveness in chronic rhinosinusitis with nasal polyps with NSAID-exacerbated respiratory diseaseIn real-world practice, most patients with CRSwNP maintained excellent control while spacing dupilumab doses far beyond every two weeks, challenging long-term fixed dosing assumptions.Remibrutinib and chronic spontaneous urticariaThis trial marks a major shift for CSU, introducing an oral, targeted option that delivers rapid symptom control and meaningful rates of complete remission.A randomized trial comparing direct challenges to penicillin skin testing for outpatient low-risk penicillin allergy evaluations in pregnancyFor pregnant patients with low-risk penicillin allergy histories, direct oral challenge proved safe, efficient, and more streamlined than traditional skin testing.Age differences in inducible laryngeal obstruction in adult populationsInducible laryngeal obstruction appears common in older adults, often presents more subtly, and frequently masquerades as asthma or anaphylaxis.Taken together, these papers reflect a broader shift in allergy care: less reflexive caution, more precision, and a growing willingness to question long-standing habits when better data emerge. Whether it's shortening observation times, tapering biologics, simplifying drug allergy evaluations, or recognizing long-ignored mimics of allergic disease, the 2025 literature nudges allergists toward care that is more precise, less reflexive, and still clinically vigilant.Have an idea for the show or a comment, send us a text!Visit the Canadian Society of Allergy and Clinical ImmunologyFind an allergist using our helpful toolFind Dr. Hanna on X, previously Twitter, @PedsAllergyDoc or CSACI @CSACI_caThe Allergist is produced for CSACI by PodCraft Productions

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZYK865. CME/MOC/CC/AAPA credit will be available until December 15, 2026.Tackling CRSwNP Management With Emerging Biologic Therapies Targeting Epithelial Cytokines: Game On! In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZYK865. CME/MOC/CC/AAPA credit will be available until December 15, 2026.Tackling CRSwNP Management With Emerging Biologic Therapies Targeting Epithelial Cytokines: Game On! In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZYK865. CME/MOC/CC/AAPA credit will be available until December 15, 2026.Tackling CRSwNP Management With Emerging Biologic Therapies Targeting Epithelial Cytokines: Game On! In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZYK865. CME/MOC/CC/AAPA credit will be available until December 15, 2026.Tackling CRSwNP Management With Emerging Biologic Therapies Targeting Epithelial Cytokines: Game On! In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZYK865. CME/MOC/CC/AAPA credit will be available until December 15, 2026.Tackling CRSwNP Management With Emerging Biologic Therapies Targeting Epithelial Cytokines: Game On! In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/ZYK865. CME/MOC/CC/AAPA credit will be available until December 15, 2026.Tackling CRSwNP Management With Emerging Biologic Therapies Targeting Epithelial Cytokines: Game On! In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca Pharmaceuticals.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/MNA865. CME/MOC/CC/AAPA credit will be available until November 18, 2026.The Type 2 Inflammation Connection in CRSwNP: Optimizing Patient Identification and Targeted Treatments In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/MNA865. CME/MOC/CC/AAPA credit will be available until November 18, 2026.The Type 2 Inflammation Connection in CRSwNP: Optimizing Patient Identification and Targeted Treatments In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/MNA865. CME/MOC/CC/AAPA credit will be available until November 18, 2026.The Type 2 Inflammation Connection in CRSwNP: Optimizing Patient Identification and Targeted Treatments In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/MNA865. CME/MOC/CC/AAPA credit will be available until November 18, 2026.The Type 2 Inflammation Connection in CRSwNP: Optimizing Patient Identification and Targeted Treatments In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

Please visit answersincme.com/860/99066167-replay3 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in nasal polyps discuss personalizing treatment selection in CRSwNP with emerging biologics. Upon completion of this activity, participants should be better able to: Specify the rationale for targeting epithelial cytokines to address unmet needs in the treatment of CRSwNP; and Design strategies to select the appropriate biologics for patients with CRSwNP, as more become available.

Please visit answersincme.com/860/99066167-replay3 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, experts in nasal polyps discuss personalizing treatment selection in CRSwNP with emerging biologics. Upon completion of this activity, participants should be better able to: Specify the rationale for targeting epithelial cytokines to address unmet needs in the treatment of CRSwNP; and Design strategies to select the appropriate biologics for patients with CRSwNP, as more become available.

Please visit answersincme.com/860/99066167-replay2 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in nasal polyps discuss the efficacy and safety of late-stage biologics in the treatment of CRSwNP. Upon completion of this activity, participants should be better able to: Interpret the clinical evidence for late-stage emerging biologics in the context of approved agents; and Design strategies to select the appropriate biologics for patients with CRSwNP, as more become available.

Please visit answersincme.com/860/99066167-replay2 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in nasal polyps discuss the efficacy and safety of late-stage biologics in the treatment of CRSwNP. Upon completion of this activity, participants should be better able to: Interpret the clinical evidence for late-stage emerging biologics in the context of approved agents; and Design strategies to select the appropriate biologics for patients with CRSwNP, as more become available.

Please visit answersincme.com/PME860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) discuss strategies for optimizing the detection and management of CRSwNP, with a focus on the role of biologics in patient-centered care. Upon completion of this activity, participants should be better able to: Identify best practices to facilitate the early detection of CRSwNP; Discuss the risk-benefit profiles of approved and emerging biologics for the treatment of CRSwNP; and Identify patient-centered, multidisciplinary strategies to integrate biologics into the treatment algorithm for patients with CRSwNP.

Persistent congestion, pressure, or a reduced sense of smell often gets mistaken for allergies or a stubborn cold when it may be something more, like chronic rhinosinusitis with nasal polyps (CRSwNP). Getting the right diagnosis is the first step toward real relief. Dr. Tonya Farmer, a board-certified ENT, joins Kortney and Dr. G to explain how chronic rhinosinusitis with nasal polyps (CRSwNP) is diagnosed. She walks us through the full evaluation: what symptoms matter, what a nasal endoscopy actually shows, when a CT scan is needed, and how type 2 inflammation fits into the picture. What we cover about diagnosing CRSwNP: Key symptoms: Persistent congestion, drainage, facial pressure, and especially loss of smell are major red flags for CRSwNP. Why duration matters: Chronic means 12 weeks or longer. If symptoms keep coming back or never truly improve, it's time to look deeper. The physical exam: ENTs use nasal endoscopy to see swelling, mucus, or polyps that aren't visible from the outside. When CT scans are needed: Imaging helps confirm sinus inflammation and shows the extent of polyp growth. Additional testing: Allergy testing, IgE levels, eosinophils, and other immune markers help identify type 2 inflammation and guide next steps. When to see a specialist: If antibiotics, steroids, or over-the-counter treatments aren't helping, ask for a referral to an allergist or ENT. Early diagnosis can prevent worsening symptoms and reduce the need for surgery. Set the foundations: Ep. 133: What is Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)? ___   Made in partnership with The Allergy & Asthma Network. Thanks to Sanofi for sponsoring today's episode.  This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

Please visit answersincme.com/860/99066167-replay1 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in nasal polyps discuss the ongoing burden of CRSwNP and the rationale for exploring novel biologics. Upon completion of this activity, participants should be better able to: Specify the rationale for targeting epithelial cytokines to address unmet needs in the treatment of CRSwNP; and Interpret the clinical evidence for late-stage emerging biologics in the context of approved agents.

Please visit answersincme.com/860/99066167-replay1 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in nasal polyps discuss the ongoing burden of CRSwNP and the rationale for exploring novel biologics. Upon completion of this activity, participants should be better able to: Specify the rationale for targeting epithelial cytokines to address unmet needs in the treatment of CRSwNP; and Interpret the clinical evidence for late-stage emerging biologics in the context of approved agents.

In Western countries, type 2 inflammation is the underlying cause of CRSwNP in ~ 80% of patients. Credit available for this activity expires: 10/24/2026 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/chronic-rhinosinusitis-nasal-polyps-reimagined-bridging-2025a1000saf?ecd=bdc_podcast_libsyn_mscpedu

Living with constant congestion, facial pressure, or a loss of smell can make daily life exhausting. For many people, these symptoms are more than just allergies or a lingering cold. They may be signs of chronic rhinosinusitis with nasal polyps (CRSwNP). Dr. Rohit Katial joins Kortney and Dr. G to unpack what CRSwNP really is, how it develops, and why type 2 inflammation plays such a key role. Together, they explain what's happening inside the sinuses, what symptoms to look for, and when it's time to see a specialist. What we cover about CRSwNP: What CRSwNP means: Chronic rhinosinusitis with nasal polyps is long-term inflammation of the nose and sinuses that lasts 12 weeks or more. What nasal polyps are: Soft, fluid-filled sacs (often “grape” or “pea” sized) that block airflow and lead to congestion and smell loss. Why it happens: Type 2 inflammation drives CRSwNP. Immune messengers like IL-4, IL-5, and IL-13 cause swelling and fluid buildup in the nasal lining. Who it affects: CRSwNP often overlaps with asthma, allergies, or aspirin sensitivity (AERD or Samter's Triad), making symptoms worse. When to seek help: If congestion, pressure, or loss of smell lasts more than 12 weeks, see an allergist or an ENT specialist. Early care can prevent sinus damage and improve breathing and quality of life. More episodes to support CRSwNP Ep. 101: What is Type 2 Inflammation? Ep. 102: Comorbidities of Type 2 Inflammation -  Connecting the Dots Between Multiple Allergic Conditions Ep. 109: Tezepelumab & Nasal Polyps - Inside the WAYPOINT Phase III Trial ___ Made in partnership with The Allergy & Asthma Network. Thanks to AstraZeneca for sponsoring today's episode.  This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/FVW865. CME/MOC/CC/AAPA credit will be available until September 28, 2026.Navigating Biologic Therapy in CRSwNP: From Patient Selection to Response Assessment In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/FVW865. CME/MOC/CC/AAPA credit will be available until September 28, 2026.Navigating Biologic Therapy in CRSwNP: From Patient Selection to Response Assessment In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/FVW865. CME/MOC/CC/AAPA credit will be available until September 28, 2026.Navigating Biologic Therapy in CRSwNP: From Patient Selection to Response Assessment In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/FVW865. CME/MOC/CC/AAPA credit will be available until September 28, 2026.Navigating Biologic Therapy in CRSwNP: From Patient Selection to Response Assessment In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/FVW865. CME/MOC/CC/AAPA credit will be available until September 28, 2026.Navigating Biologic Therapy in CRSwNP: From Patient Selection to Response Assessment In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA information, and to apply for credit, please visit us at PeerView.com/FVW865. CME/MOC/CC/AAPA credit will be available until September 28, 2026.Navigating Biologic Therapy in CRSwNP: From Patient Selection to Response Assessment In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis program is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

Please visit answersincme.com/860/MED-RESP-03359-replay to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, ENT and allergy experts present strategies for incorporating the latest biologic therapies for patients with chronic rhinosinusitis with nasal polyps (CRSwNP) via case-based challenges. Upon completion of this activity, participants should be better able to: Identify patients with CRSwNP who are candidates for biologic therapies according to guideline recommendations; Select appropriate biologic therapies for patients with CRSwNP based on patient-, disease-, and drug-related factors; Apply guideline recommendations for monitoring response to biologic treatment of CRSwNP; and Outline treatment sequencing strategies to optimize the management of CRSwNP.

CME credits: 1.00 Valid until: 12-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/collaborative-care-for-crswnp-expert-and-patient-insights/36695/ Chronic rhinosinusitis with nasal polyps (CRSwNP) presents a large burden on more than 3 million patients with the conditions — especially when intertwined with asthma and allergy. Join our discussion between patients with CRSwNP and leading experts in ENT, allergy, and pulmonary medicine as they: Breakdown how to recognize key inflammatory patterns. Discuss the burden of illness and goals of treatment Interpret clinical trial data on biologic treatments. Apply a collaborative care approach to improve patient outcomes. Watch now to explore cases with patient panelists, expert perspectives, and evidence-based strategies for managing CRSwNP in multidisciplinary settings. =

CME credits: 1.00 Valid until: 12-09-2026 Claim your CME credit at https://reachmd.com/programs/cme/collaborative-care-for-crswnp-expert-and-patient-insights/36695/ Chronic rhinosinusitis with nasal polyps (CRSwNP) presents a large burden on more than 3 million patients with the conditions — especially when intertwined with asthma and allergy. Join our discussion between patients with CRSwNP and leading experts in ENT, allergy, and pulmonary medicine as they: Breakdown how to recognize key inflammatory patterns. Discuss the burden of illness and goals of treatment Interpret clinical trial data on biologic treatments. Apply a collaborative care approach to improve patient outcomes. Watch now to explore cases with patient panelists, expert perspectives, and evidence-based strategies for managing CRSwNP in multidisciplinary settings. =

How do we integrate biologics into the existing stepwise treatment model for chronic rhinosinusitis with nasal polyps (CRSwNP)? In this episode, Dr. Reena Mehta, an allergist from Uptown Allergy and Asthma in New Orleans, discusses the use of biologics for treating chronic rhinosinusitis with nasal polyps. ---SYNPOSISDr. Mehta elaborates on the common presentations of patients, the role of biologics such as dupilumab and tezepelumab, and the nuances of patient management post-sinus surgery. Dr. Mehta also covers the workup process, the significance of patient comorbidities like asthma and allergies, and the future perspectives on biologic treatments. Practical aspects of biologic therapy, including insurance hurdles, patient compliance, and the effectiveness of various biologics are thoroughly examined.---TIMESTAMPS00:00 - Introduction 02:27 - Understanding Chronic Rhinosinusitis with Nasal Polyps & Presentation05:22 - Workup and Management of Nasal Polyps07:31 - Treatment Options: Steroids and Biologics15:28 - Tezepelumab: A New Tool in the Toolkit25:03 - Side Effects and Safety of Biologics28:59 - Insurance and Approval Challenges36:14 - Long-Term Safety and Efficacy38:47 - Pediatric Considerations and Future Directions41:37 - Collaboration Between ENT and Allergy Specialists45:07 - Conclusion and Final Thoughts---RESOURCESDr. Reena Mehtahttps://uptownallergyasthma.com/allergist-dr-reena-mehta/

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NFR865. CME/MOC/CC/AAPA/IPCE credit will be available until May 25, 2026.Biologic Therapy for CRSwNP: Exploring the Advanced Practice Provider's Role in Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NFR865. CME/MOC/CC/AAPA/IPCE credit will be available until May 25, 2026.Biologic Therapy for CRSwNP: Exploring the Advanced Practice Provider's Role in Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NFR865. CME/MOC/CC/AAPA/IPCE credit will be available until May 25, 2026.Biologic Therapy for CRSwNP: Exploring the Advanced Practice Provider's Role in Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NFR865. CME/MOC/CC/AAPA/IPCE credit will be available until May 25, 2026.Biologic Therapy for CRSwNP: Exploring the Advanced Practice Provider's Role in Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NFR865. CME/MOC/CC/AAPA/IPCE credit will be available until May 25, 2026.Biologic Therapy for CRSwNP: Exploring the Advanced Practice Provider's Role in Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NFR865. CME/MOC/CC/AAPA/IPCE credit will be available until May 25, 2026.Biologic Therapy for CRSwNP: Exploring the Advanced Practice Provider's Role in Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

In this episode, host Dr. Marc Dubin speaks with Dr. Alan Workman and Dr. Jim Palmer. They discuss the recently published Original Article: “Assessing adequacy of surgical extent in CRSwNP: The Completion of Surgery Index”. The full manuscript is available online in the International Forum of Allergy and Rhinology. Listen and subscribe for free to […]

Have you wondered why having more drug options matters for chronic rhinosinusitis with nasal polyps? In the inaugural episode of our new series, The Itch Review, co-hosts Kortney and Dr. Payel Gupta, along with special guest Dr. Michael Blaiss, unpack the journal article "Tezepelumab in Adults with Severe Chronic Rhinosinusitis with Nasal Polyps," published in the New England Journal of Medicine on March 1, 2025. This article is about the Phase III WAYPOINT trial of tezepelumab. Already approved for severe asthma, this once-monthly biologic is now showing promise in chronic rhinosinusitis with nasal polyps (CRSwNP). Over 52 weeks, 408 patients were randomized to receive 210 mg of tezepelumab every four weeks or placebo. Researchers tracked nasal-polyp scores, congestion, sense of smell, and rates of rescue surgery. In this episode, we provide a brief overview of what CRSwNP is, why inflammation drives polyp formation and how blocking TSLP fits into today's biologics options. We'll walk you through the WAYPOINT Phase III design, explain the primary and secondary endpoints, and translate the headline results into what they mean for real-world patients who've exhausted their treatment options. ➡️ Get the infographic here. What we cover in our episode about treating chronic rhinosinusitis with nasal polyps with tezepelumab CRSwNP basics & tezepelumab mechanism of action: How nasal polyps form and why targeting TSLP can reduce inflammation WAYPOINT design: 52-week, placebo-controlled Phase III study in 408 patients  Primary endpoints: Mean change in nasal polyp score and nasal-congestion score Secondary endpoints: Smell recovery, need for rescue surgery or systemic steroids, and quality-of-life measures Why choice matters: Every CRSwNP patient responds differently, and having more treatment options means more chances to find the right fit   Made in partnership with The Allergy & Asthma Network. Thanks to AstraZeneca for sponsoring today's episode. This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let's dive into the latest updates impacting clinicians and healthcare providers like you! Interested in a more traditional, text rundown? Check out the HCPFive! Top 5 healthcare headlines for March 9-16, 2025: 1. CagriSema Yields Nearly 16% Weight Loss in Phase 3 REDEFINE 2 Trial In the Phase 3 REDEFINE 2 trial, CagriSema showed weight reduction in adults with obesity or overweight and type 2 diabetes, outperforming placebo. 2. Lorundrostat Significantly Lowers Blood Pressure in Key Hypertension Trials The Phase 3 Launch-HTN and Phase 2 Advance-HTN trials showed lorundrostat effectively reduced blood pressure in uncontrolled or resistant hypertension with a favorable safety profile. 3. PharmaTher Receives New Early June FDA Goal Date for Ketamine PharmaTher announced the FDA set a new Priority Review goal date of June 4, 2025, for ketamine to treat anesthesia, pain, mental health, and neurological conditions. 4. FDA Awards Fast Track Designation to ATSN-201 Gene Therapy for XLRS The FDA granted Fast Track designation to ATSN-201 for X-linked retinoschisis, allowing Atsena Therapeutics to seek Priority Review for their gene therapy. 5. FDA Approves First Interchangeable Biosimilar for Omalizumab The FDA approved omalizumab-igec (OMLYCLO) as the first interchangeable biosimilar to Xolair for asthma, CRSwNP, IgE-mediated food allergy, and CSU.

Why do conditions like asthma, nasal polyps, or eczema become more severe when they coexist? Kortney and Dr. Payel Gupta are joined by Dr. Michael Blaiss to explore the common thread linking multiple allergic and inflammatory diseases: Type 2 Inflammation. If you've ever wondered why certain conditions often appear together, this deep dive will help you connect the dots. Type 2 Inflammation is a hot topic in immunology because it's the engine that drives many allergic and inflammatory diseases. It's also the key to modern treatment strategies, including targeted biologic therapies. Dr. Blaiss explains how clinicians recognize multiple Type 2-driven conditions in the same patient, why it is important to know the connection between multiple conditions and Type 2 inflammation, and the big-picture benefits of treating inflammation aggressively to prevent complications. What We Cover in our Episode about The Diseases Related to Type 2 Inflammation Conditions Related to Type 2 Inflammation: Explore how chronic rhinosinusitis with nasal polyps (CRSwNP), rhinitis, asthma, atopic dermatitis (eczema), prurigo nodularis, eosinophilic esophagitis (EoE), and food allergies can all share a common inflammatory pathway. The Likelihood of Having Multiple Type 2 Conditions: How often do patients have more than one condition related to Type 2 Inflammation, and why is recognizing overlap a potential game-changer for diagnosis and treatment? Treating the Root Inflammation vs. Individual Symptoms: Discover how clinicians decide whether to address each condition separately or tackle the underlying Type 2 inflammatory process affecting them all. Markers & Personalized Medicine: Dr. Blaiss discusses whether potential tests, such as eosinophil counts or IgE levels, can confirm Type 2 inflammation. He also explains how knowing you have Type 2 Inflammation can help guide targeted therapy. Prevention & Aggressive Intervention: Understand why it's crucial to treat inflammation early to reduce the risk of developing multiple Type 2 conditions and how this proactive approach benefits long-term health. Want to know more? Type 2 Inflammation Overview – Explains the role of Type 2 inflammation in conditions like asthma and nasal polyps. This podcast is for informational purposes only and does not substitute for professional medical advice. If you have any medical concerns, always consult with your healthcare provider. Produced in partnership with The Allergy & Asthma Network. Thanks to Sanofi and Regeneron for sponsoring today's episode. While they support the show, all opinions are our own, and sponsorship doesn't influence our content or editorial decisions. Any mention of brands is for informational purposes and not an endorsement.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NMD865. CME/MOC/CC/AAPA/IPCE credit will be available until February 17, 2026.Mastering the Art and Science of Biologic Therapy for CRSwNP: Who Are the Candidates and How Do You Manage Their Care? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/NMD865. CME/MOC/CC/AAPA/IPCE credit will be available until February 17, 2026.Mastering the Art and Science of Biologic Therapy for CRSwNP: Who Are the Candidates and How Do You Manage Their Care? In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc and Sanofi.Disclosure information is available at the beginning of the video presentation.

Please visit answersincme.com/KSU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in otolaryngology discuss the role of biologic therapies in chronic rhinosinusitis with nasal polyps (CRSwNP). Upon completion of this activity, participants should be better able to: Recognize considerations for initiating treatment with a biologic therapy in patients with CRSwNP; Review the clinical implications of the latest efficacy and safety data for novel approved biologics in CRSwNP; and Outline strategies to optimize the use of biologics in patients with CRSwNP over the long term.

Please visit answersincme.com/KSU860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in otolaryngology discuss the role of biologic therapies in chronic rhinosinusitis with nasal polyps (CRSwNP). Upon completion of this activity, participants should be better able to: Recognize considerations for initiating treatment with a biologic therapy in patients with CRSwNP; Review the clinical implications of the latest efficacy and safety data for novel approved biologics in CRSwNP; and Outline strategies to optimize the use of biologics in patients with CRSwNP over the long term.

Please visit answersincme.com/YWD860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in rhinology discusses the use of biologics for the management of chronic rhinosinusitis with nasal polyps (CRSwNP). Upon completion of this activity, participants should be better able to: Identify key considerations for initiating a biologic therapy in patients with CRSwNP; Discuss the clinical impact of the latest data for novel approved biologics in CRSwNP; and Apply best practice approaches for management of biologics in patients with CRSwNP. This activity is intended for US healthcare professionals only.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/CC information, and to apply for credit, please visit us at PeerView.com/AYT865. CME/MOC/CC credit will be available until November 9, 2025.Uncovering the Role of Epithelial Cytokines in CRSwNP: Examining the Clinical Implications of New Approaches with Targeted Biologic Therapy In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca LP.Disclosure information is available at the beginning of the video presentation.

Are you curious about how biologic medications are transforming the treatment of asthma, eczema, allergies, and more? Dr. Perdita Permaul joins Dr. Gupta and Kortney to discuss the available biologic medications for allergic conditions. We walk through the eight biologics currently available for allergic diseases, explaining how these medications target different parts of the immune system to treat allergic conditions more effectively than traditional medications. Dr. Permaul explains how biologics have evolved since 2003 and how they are changing the way allergic conditions are treated. She also explains why some of the biologics treat multiple diseases, whereas some are only approved for one.  What we cover in our episode about the available biologics for allergic conditions How biologics work for allergic conditions: We unpack how biologic medications target specific parts of the immune system, reducing inflammation and improving the quality of life for patients with allergic diseases. History and evolution of biologics: Dr. Permaul walks us through the timeline of biologics, starting with Xolair in 2003 and how these treatments have expanded to target other conditions over time. Which biologics treat which conditions: From asthma and eczema to food allergies and nasal polyps, we break down which biologics are available and how they help patients with allergic conditions. Future of biologics: Dr. Permaul discusses the potential of biologics to be used for more conditions in the future, including ongoing research into food allergy treatments. Biologics Cheat Sheet Below is a list of the 8 biologics discussed in this episode. We have briefly outlined their mechanism of action along with the approved conditions and ages the drug is available for presecription.  Omalizumab (Xolair) Xolair works by binding to IgE to prevent allergic reactions. It has since been approved for chronic hives, nasal polyps, and food allergies. Allergic asthma: 6+ Chronic idiopathic urticaria (hives: 12+ Chronic rhinosinusitis with nasal polyps (CRSwNP): 18+ Food allergies:1+ Mepolizumab (Nucala) Targets and blocks interleukin-5 (IL-5) play a key role in the activation and priming of eosinophils, a type of white blood cell that causes inflammation in asthma. Eosinophilic Asthma: 6+ CRSwNP: 18+ Eosinophilic Granulomatosis with Polyangiitis (EGPA): 18+ Hypereosinophilic Syndrome: ≥6 months Reslizumab (Cinqair) Targets and blocks interleukin-5 (IL-5). Eosinophilic asthma: 18+ Benralizumab (Fasenra) Binds to the IL-5 receptor, preventing eosinophils from growing and causing inflammation. Eosinophilic asthma: 6+ Eosinophilic Granulomatosis with Polyangiitis (EGPA): 18+ Dupilumab (Dupixent) Targets and blocks IL-4 and IL-13 to reduce inflammation Asthma: 6+ Atopic Dermatitis: 6 months+ CRSwNP: 18+ Eosinophilic Esophagitis (EoE): 1+ (> 33 lbs) Approved for prurigo nodularis (PN): 18+ Tezepelumab (Tezspire) Blocks thymic stromal lymphopoietin (TSLP). Asthma: 12+ Tralokinumab (Adbry, Adtralza) Targets and neutralizes interleukin-13 (IL-13). Atopic dermatitis: 12+ Lebrikizumab (Ebglyss) Targets and neutralizes interleukin-13 (IL-13). Atopic dermatitis: 12+ (> 40 lbs) ________ This podcast is made in partnership with The Allergy & Asthma Network. Thanks to Sanofi-Regeneron for sponsoring today's episode. While they support the show, all opinions are our own, and sponsorship doesn't influence our content or editorial decisions. Any mention of brands is for informational purposes and not an endorsement. Disclaimer: This podcast is for informational purposes only and does not substitute professional medical advice. Always consult with your healthcare provider for any medical concerns.

Please visit answersincme.com/VWM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in allergy discusses how to optimize the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) and comorbidities with biologic therapies. Upon completion of this activity, participants should be better able to: Identify patients with CRSwNP who are candidates for biologic therapies according to guideline recommendations; Describe best practices for monitoring response to biologic treatment of CRSwNP; and Outline treatment sequencing strategies to optimize the management of CRSwNP. This activity is intended for US healthcare professionals only.